FOI release

Function of excipients in Alimemazine Tartrate 7.5 mg/5 ml Syrup

Some or all of the information requested may not have been provided because we determined that the request was vexatious.

Case reference FOI2026/01016

Received 9 September 2026

Published 15 September 2026

Request

Dear MHRA, I am reviewing the Summary of Product Characteristics (SmPC) for Alimemazine Tartrate 7.5 mg/5 ml Syrup (PL 17780/0465), for which Zentiva Pharma UK Limited is the Marketing Authorisation Holder. I note that sodium sulphite anhydrous (E221) and sodium metabisulphite (E223) are included under the section “Excipients with known effect”, while L(+) ascorbic acid is listed in the full list of excipients in Section 6.1. Could you please confirm the function/role of the following excipients in this medicinal product: Sodium sulphite anhydrous (E221) Sodium metabisulphite (E223) L(+) ascorbic acid

Response

See attached

Documents

• FOI2026_1016 (redacted).pdf (961.1 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.